Clinical effect of short-term regimen containing levofloxacin in the treatment of newly diagnosed bacteria-positive pulmonary tuberculosis

doi:10.19983/j.issn.2096-8493.20210145

Abstract

Abstract:

Objective: To analyze the clinical effect of short-term regimen containing levofloxacin (Lfx) in the treatment of newly diagnosed bacteria-positive pulmonary tuberculosis. Methods: A prospective study was conducted in 132 newly diagnosed bacteria-positive pulmonary tuberculosis patients in Shantou Tuberculosis Prevention and Treatment Institution from January 2017 to December 2019. The patients were consecutively numbered and randomly divided into observation group (n=68) and control group (n=64). The control group was treated with routine 2H-R-Z-E/4H-R scheme (H: isoniazid; R: rifampicin; Z: pyrazinamide; E: ethambutol), and the observation group was treated with 4.5Lfx-H-R-E-Z scheme. The cure rate, sputum negative conversion rate, focus absorption, incidence of adverse drug reactions and recurrence rate were compared between the two groups. Results: The cure rate of the observation group was 100.0% (68/68), which was significantly higher than that of the control group (90.6% (58/64))(Fisher’s exact probability method, P=0.011). The negative conversion rates of sputum bacteria in the observation group and the control group at the end of 2 months (8 weeks) of treatment were 97.1% (66/68) and 96.9% (62/64), respectively, with no significant difference (Fisher’s exact probability method, P>0.05). The total effective rate of lesion absorption was 100.0% (68/68) in the observation group and 90.6% (58/64) in the control group, with no significant difference (χ²=3.552, P=0.470). The incidence of adverse drug reactions in the observation group and the control group were 20.6% (14/68) and 18.8% (12/64), respectively, with no significant difference (χ²=0.070, P=0.791). After 2 years of follow-up, the recurrence rate was 2.9% (2/68) in the observation group and 3.1% (2/64) in the control group, with no significant difference (Fisher’s exact probability method, P=1.000). Conclusion: The short-term regimen containing Lfx is effective and safe in the treatment of newly diagnosed bacteria-positive pulmonary tuberculosis.

Key words: Tuberculosis,pulmonary, Quinolones, Drug therapy, Therapeutic uses

CLC Number:

R521
R978.3

CHEN Zhuang-hao, LIN Jian-xiong, ZENG Li-xiang. Clinical effect of short-term regimen containing levofloxacin in the treatment of newly diagnosed bacteria-positive pulmonary tuberculosis[J]. Journal of Tuberculosis and Lung Disease , 2022, 3(1): 19-21. doi: 10.19983/j.issn.2096-8493.20210145

Figures/Tables 1

References 5

[1]	段鸿飞, 初乃惠. 抗结核药品临床试验疗效评价指标的研究进展. 中国防痨杂志, 2021, 43(1):96-99. doi: 10.3969/j.issn.1000-6621.2021.01.018. doi: 10.3969/j.issn.1000-6621.2021.01.018
[2]	许惠敏, 罗浓伟. 含左氧氟沙星方案治疗老年复治涂阳肺结核的临床价值. 北方药学, 2020, 17(3):132-133. doi: 10.3969/j.issn.1672-8351.2020.03.098. doi: 10.3969/j.issn.1672-8351.2020.03.098
[3]	Wallis RS, Peppard T, Hermann D. Month 2 culture status and treatment duration as predictors of recurrence in pulmonary tuberculosis: model validation and update. PLoS One, 2015, 10(4):e0125403. doi: 10.1371/journal.pone.0125403. doi: 10.1371/journal.pone.0125403 URL
[4]	Jawahar MS, Banurekha VV, Paramasivan CN, et al. Randomized clinical trial of thrice-weekly 4-month moxifloxacin or gatifloxacin containing regimens in the treatment of new sputum positive pulmonary tuberculosis patients. PLoS One, 2013, 8(7):e67030. doi: 10.1371/journal.pone.0067030. doi: 10.1371/journal.pone.0067030 URL
[5]	Velayutham BV, Allaudeen IS, Sivaramakrishnan GN, et al. Sputum culture conversion with moxifloxacin-containing regimens in the treatment of patients with newly diagnosed sputum-positive pulmonary tuberculosis in South India. Clin Infect Dis, 2014, 59(10):e142-e149. doi: 10.1093/cid/ciu550. doi: 10.1093/cid/ciu550 URL

组别	例数	全吸[例 (构成比,%)]	显吸[例 (构成比,%)]	吸收[例 (构成比,%)]	不变[例 (构成比,%)]	恶化[例 (构成比,%)]	总有效[例 (有效率,%)]
观察组	68	46(67.6)	12(17.6)	10(14.8)	0(0.0)	0(0.0)	68(100.0)
对照组	64	36(56.3)	12(18.8)	10(15.6)	6(9.3)	0(0.0)	58(90.6)

[1]	Yan Qinghu, Xue Feng, Yu Yong, Qin Yi, Yan Qingmei, Cui Jia. The value of ultrasound-guided microwave ablation in the treatment of localized tuberculous lesions [J]. Journal of Tuberculosis and Lung Disease, 2025, 6(1): 55-60.
[2]	Chang Li, Ren Hong, Guan Xueqing, Pang Youquan, Zhen Chunying, Bian Nannan, Sun Suqin. Correlation between vascular endothelial growth factor (VEGF) expression levels and therapeutic outcomes in patients with malignant pleural effusion [J]. Journal of Tuberculosis and Lung Disease, 2024, 5(6): 533-539.
[3]	Zhang Yidan, Gu Fen, Li Nannan. Current status and nursing research progress of long-term oxygen therapy for patients with chronic obstructive pulmonary disease [J]. Journal of Tuberculosis and Lung Disease, 2024, 5(3): 249-253.
[4]	You Guoqing, Liu Wenguo, Feng Xin, Yu Min, Shi Lin, Hu Yan. Analysis of fluoroquinolones resistance in multidrug-resistant tuberculosis patients in Chongqing from 2020 to 2022 [J]. Journal of Tuberculosis and Lung Disease, 2023, 4(6): 475-479.
[5]	Lu Yu, Wang Xiaodong. Research progress of non-drug therapy for chronic obstructive pulmonary disease-related fatigue [J]. Journal of Tuberculosis and Lung Disease, 2023, 4(3): 240-245.
[6]	Wang Guowei, Liang Yachong, Liu Yufei, Li Cuiqiao, He Ping. Efficacy observation of Xiaoluo Sanjie Powder combined with conventional anti-tuberculosis drugs in the treatment of infiltrating lymph node tuberculosis [J]. Journal of Tuberculosis and Lung Disease, 2023, 4(1): 60-65.
[7]	Huang Wei, Shen Yinzhong. Key issues of diagnosis and treatment of acquired immunodeficiency syndrome complicated with tuberculosis [J]. Journal of Tuberculosis and Lung Disease, 2022, 3(6): 431-436.
[8]	Lou Nannan, Guo Jing, Ma Xiang, Gai Zhongtao. Research progress in pathological mechanism and treatment of cough variant asthma [J]. Journal of Tuberculosis and Lung Disease, 2022, 3(6): 521-525.
[9]	TIAN Yao, LIU Hui-min, FU Man-jiao, BEI Cheng-li. Diagnosis and treatment of tuberculosis complicated with diabetes [J]. Journal of Tuberculosis and Lung Disease, 2022, 3(2): 91-95.
[10]	DENG Guo-fang, LEI Jian-ping. Analysis on diagnosis and treatment of coronavirus disease 2019(COVID-19) [J]. Journal of Tuberculosis and Lung Health, 2020, 9(1): 7-10.
[11]	WANG Chun-ting, LI Ya-qi, MI Yan, MO Nian-chun, LIU Hong-yan, LE Xing, ZHOU Li, WU Bi-feng, HAN Shi-yun, BAI Li-qiong, ZHANG Chuan-fang. Monitoring of pulmonary function in patients with active tuberculosis during anti-tuberculosis treatment [J]. Journal of Tuberculosis and Lung Disease, 2020, 1(1): 39-44.
[12]	Ni WANG,Fei HUANG,Hui ZHANG. Implementation electronic medication monitor in tuberculosis medication management [J]. Journal of Tuberculosis and Lung Health, 2019, 8(4): 244-248.
[13]	Song YANG,Xiao-feng YAN. Current status and future prospects on the treatment of multi/extensively drug-resistant tuberculosis with bedaquiline [J]. Journal of Tuberculosis and Lung Health, 2019, 8(4): 249-252.
[14]	MA Jin-bao,MA Ting-ting,REN Fei,YANG Hong.. Analysis of hypokalemia caused by capreomycin in patients with multidrug-resistant tuberculosis [J]. Journal of Tuberculosis and Lung Health, 2019, 8(3): 183-187.
[15]	Shuang LIANG,Dong-wei HAN,Wei ZHONG,Ning MAO,Yi LIU,Yi-wen JIANG. Analysis of effect of FDC chemethorapy combined with levofloxacin in patients with smear positive pulmonary tuberculosis [J]. Journal of Tuberculosis and Lung Health, 2019, 8(2): 149-152.